Ibiglustat-L-Malic-acid-Venglustat-L-Malic-acid-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEIbiglustat L-Malic acidCat. No.: HY-16743ACAS No.: 1629063-78-0Synonyms: Venglustat (L-Malic acid); SAR402671 (L-Malic acid);GZ402671 (L-Malic acid)分式: CHFNOS分量: 523.57作靶点: Others作通路: Others储存式: Powder -20C 3 years4C 2 yearsIn s

2、olvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 102 mg/mL (194.82 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.9100 mL 9.5498 mL 19.0996 mL5 mM 0.3820 mL 1.9100 mL 3.8199 mL10 mM 0.1910 mL 0.9550 mL 1.9100 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式

3、和期限。BIOLOGICAL ACTIVITY物活性 Ibiglustat L-Malic acid (Venglustat L-Malic acid)种潜在的帕森病、法布病和谢病的治疗药物，是选择性的、葡糖神经酰胺合成酶 (GCS) 的变构抑制剂，能通过脑屏障 1 2 3。IC50 & Target Glucosylceramide synthase 1.1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE体外研究 Ibiglustat (SAR402671) (1 M, 15 days) treated FD cells are close t

4、o the physiological level in untreated WTcells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve toameliorate the abundant levels of this sphingolipid in FD cardiomyocytes 4.REFERENCES1. WO 2015089067 A1.2. Iva Stojkovska, et al. Molecular mechanisms

5、 of -synuclein and GBA1 in Parkinsons disease. Cell Tissue Res. 2017.3. Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 16871700.4. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014Nov;37(6):1013-22.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;